These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

302 related articles for article (PubMed ID: 27276722)

  • 21. Cerebrospinal fluid levels of β-amyloid 1-42, but not of tau, are fully changed already 5 to 10 years before the onset of Alzheimer dementia.
    Buchhave P; Minthon L; Zetterberg H; Wallin AK; Blennow K; Hansson O
    Arch Gen Psychiatry; 2012 Jan; 69(1):98-106. PubMed ID: 22213792
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Alzheimer's disease cerebro-spinal fluid biomarkers: A clinical research tool sometimes useful in daily clinical practice of memory clinics for the diagnosis of complex cases].
    Magnin E; Dumurgier J; Bouaziz-Amar E; Bombois S; Wallon D; Gabelle A; Lehmann S; Blanc F; Bousiges O; Hannequin D; Jung B; Miguet-Alfonsi C; Quillard M; Pasquier F; Peoc'h K; Laplanche JL; Hugon J; Paquet C;
    Rev Med Interne; 2017 Apr; 38(4):250-255. PubMed ID: 27890382
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Decreasing body mass index is associated with cerebrospinal fluid markers of Alzheimer's pathology in MCI and mild dementia.
    Mathys J; Gholamrezaee M; Henry H; von Gunten A; Popp J
    Exp Gerontol; 2017 Dec; 100():45-53. PubMed ID: 29054536
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Incremental value of biomarker combinations to predict progression of mild cognitive impairment to Alzheimer's dementia.
    Frölich L; Peters O; Lewczuk P; Gruber O; Teipel SJ; Gertz HJ; Jahn H; Jessen F; Kurz A; Luckhaus C; Hüll M; Pantel J; Reischies FM; Schröder J; Wagner M; Rienhoff O; Wolf S; Bauer C; Schuchhardt J; Heuser I; Rüther E; Henn F; Maier W; Wiltfang J; Kornhuber J
    Alzheimers Res Ther; 2017 Oct; 9(1):84. PubMed ID: 29017593
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cerebrospinal Fluid Biomarkers for Early and Differential Alzheimer's Disease Diagnosis.
    Bjerke M; Engelborghs S
    J Alzheimers Dis; 2018; 62(3):1199-1209. PubMed ID: 29562530
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The association between biomarkers in cerebrospinal fluid and structural changes in the brain in patients with Alzheimer's disease.
    Li X; Li TQ; Andreasen N; Wiberg MK; Westman E; Wahlund LO
    J Intern Med; 2014 Apr; 275(4):418-27. PubMed ID: 24237038
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Interactions between amyloid-β and tau in cerebrospinal fluid of people with mild cognitive impairment and Alzheimer's disease.
    Kristofikova Z; Ricny J; Kolarova M; Vyhnalek M; Hort J; Laczo J; Sirova J; Ripova D
    J Alzheimers Dis; 2014; 42 Suppl 3():S91-8. PubMed ID: 24670397
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Relationship between β-Secretase, inflammation and core cerebrospinal fluid biomarkers for Alzheimer's disease.
    Alcolea D; Carmona-Iragui M; Suárez-Calvet M; Sánchez-Saudinós MB; Sala I; Antón-Aguirre S; Blesa R; Clarimón J; Fortea J; Lleó A
    J Alzheimers Dis; 2014; 42(1):157-67. PubMed ID: 24820015
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Performance Evaluation of an Automated ELISA System for Alzheimer's Disease Detection in Clinical Routine.
    Chiasserini D; Biscetti L; Farotti L; Eusebi P; Salvadori N; Lisetti V; Baschieri F; Chipi E; Frattini G; Stoops E; Vanderstichele H; Calabresi P; Parnetti L
    J Alzheimers Dis; 2016 Jul; 54(1):55-67. PubMed ID: 27447425
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Biomarkers for Alzheimer's disease: current status and prospects for the future.
    Blennow K; Zetterberg H
    J Intern Med; 2018 Dec; 284(6):643-663. PubMed ID: 30051512
    [TBL] [Abstract][Full Text] [Related]  

  • 31. CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment.
    Mattsson N; Zetterberg H; Hansson O; Andreasen N; Parnetti L; Jonsson M; Herukka SK; van der Flier WM; Blankenstein MA; Ewers M; Rich K; Kaiser E; Verbeek M; Tsolaki M; Mulugeta E; Rosén E; Aarsland D; Visser PJ; Schröder J; Marcusson J; de Leon M; Hampel H; Scheltens P; Pirttilä T; Wallin A; Jönhagen ME; Minthon L; Winblad B; Blennow K
    JAMA; 2009 Jul; 302(4):385-93. PubMed ID: 19622817
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Factors that influence the levels of cerebrospinal fluid biomarkers in memory clinic patients.
    Knapskog AB; Eldholm RS; Braekhus A; Engedal K; Saltvedt I
    BMC Geriatr; 2017 Sep; 17(1):210. PubMed ID: 28893185
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Simultaneous analysis of cerebrospinal fluid biomarkers using microsphere-based xMAP multiplex technology for early detection of Alzheimer's disease.
    Kang JH; Vanderstichele H; Trojanowski JQ; Shaw LM
    Methods; 2012 Apr; 56(4):484-93. PubMed ID: 22503777
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Relations between personality changes and cerebrospinal fluid biomarkers of Alzheimer's disease pathology.
    Tautvydaitė D; Antonietti JP; Henry H; von Gunten A; Popp J
    J Psychiatr Res; 2017 Jul; 90():12-20. PubMed ID: 28213293
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prediction of Alzheimer disease in subjects with amnestic and nonamnestic MCI.
    Vos SJ; van Rossum IA; Verhey F; Knol DL; Soininen H; Wahlund LO; Hampel H; Tsolaki M; Minthon L; Frisoni GB; Froelich L; Nobili F; van der Flier W; Blennow K; Wolz R; Scheltens P; Visser PJ
    Neurology; 2013 Mar; 80(12):1124-32. PubMed ID: 23446677
    [TBL] [Abstract][Full Text] [Related]  

  • 36. T1rho MRI and CSF biomarkers in diagnosis of Alzheimer's disease.
    Haris M; Yadav SK; Rizwan A; Singh A; Cai K; Kaura D; Wang E; Davatzikos C; Trojanowski JQ; Melhem ER; Marincola FM; Borthakur A
    Neuroimage Clin; 2015; 7():598-604. PubMed ID: 25844314
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cerebrospinal Fluid Biomarkers for the Differential Diagnosis between Alzheimer's Disease and Frontotemporal Lobar Degeneration: Systematic Review, HSROC Analysis, and Confounding Factors.
    Rivero-Santana A; Ferreira D; Perestelo-Pérez L; Westman E; Wahlund LO; Sarría A; Serrano-Aguilar P
    J Alzheimers Dis; 2017; 55(2):625-644. PubMed ID: 27716663
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Diagnostic Accuracy of Cerebrospinal Fluid Amyloid-β Isoforms for Early and Differential Dementia Diagnosis.
    Struyfs H; Van Broeck B; Timmers M; Fransen E; Sleegers K; Van Broeckhoven C; De Deyn PP; Streffer JR; Mercken M; Engelborghs S
    J Alzheimers Dis; 2015; 45(3):813-22. PubMed ID: 25633670
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Recommendations for cerebrospinal fluid Alzheimer's disease biomarkers in the diagnostic evaluation of mild cognitive impairment.
    Herukka SK; Simonsen AH; Andreasen N; Baldeiras I; Bjerke M; Blennow K; Engelborghs S; Frisoni GB; Gabryelewicz T; Galluzzi S; Handels R; Kramberger MG; Kulczyńska A; Molinuevo JL; Mroczko B; Nordberg A; Oliveira CR; Otto M; Rinne JO; Rot U; Saka E; Soininen H; Struyfs H; Suardi S; Visser PJ; Winblad B; Zetterberg H; Waldemar G
    Alzheimers Dement; 2017 Mar; 13(3):285-295. PubMed ID: 28341066
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Do CSF total tau, phosphorylated tau, and beta-amyloid 42 help to predict progression of mild cognitive impairment to Alzheimer's disease? A systematic review and meta-analysis of the literature.
    Diniz BS; Pinto Júnior JA; Forlenza OV
    World J Biol Psychiatry; 2008; 9(3):172-82. PubMed ID: 17886169
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.